Academic Journal

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Συγγραφείς: Foster, G, Irving, W, Cheung, M, Walker, A, Hudson, B, Verma, S, McLauchlan, J, Mutimer, D, Brown, A, Gelson, W, MacDonald, D, Agarwal, K, HCV Research, UK
Στοιχεία εκδότη: Elsevier
Έτος έκδοσης: 2019
Συλλογή: Oxford University Research Archive (ORA)
Περιγραφή: Background & Aims: All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcomes in treated and untreated patients with decompensated cirrhosis. Methods: Patients with HCV and decompensated cirrhosis or at risk of irreversible disease were treated in an expanded access programme (EAP) in 2014. Treatment, by clinician choice, was with sofosbuvir, ledipasvir or daclatasvir, with or without rib-avirin. For functional outcome comparison, untreated patients with HCV and decompensated cirrhosis who were registered on a database 6 months before treatment was available were retro-spectively studied. Primary endpoint was sustained virological response 12 weeks post antiviral treatment (treated cohort) and the secondary endpoint (both cohorts) was adverse outcomes (worsening in MELD score or serious adverse event) within 6 months. Results: 467 patients received treatment (409 decompensated cirrhosis). Viral clearance was achieved in 381 patients (81.6%)– 209 from 231 (90.5%) with genotype 1 and 132 from 192(68.8%) with genotype 3. MELD scores improved in treated patients (mean change -0.85) but worsened in untreated patients (mean + 0.75) (p<0.0001). Patients with initial serumalbumin <35 g/L, aged >65 or with low (<135 mmol/L) baselineserum sodium concentrations were least likely to benefit from therapy. Conclusions: All oral DAAs effectively cured HCV in patients with advanced liver disease. Viral clearance was associated with improvement in liver function within 6 months compared to untreated patients. The longer term impact of HCV treatment in patients with decompensated cirrhosis remains to be determined.
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: English
Relation: https://doi.org/10.1016/j.jhep.2016.01.029
DOI: 10.1016/j.jhep.2016.01.029
Διαθεσιμότητα: https://doi.org/10.1016/j.jhep.2016.01.029
https://ora.ox.ac.uk/objects/uuid:72cd8280-5289-4a1d-9eaf-9fe68f2fe2cd
Rights: info:eu-repo/semantics/openAccess
Αριθμός Καταχώρησης: edsbas.69C44DA7
Βάση Δεδομένων: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://doi.org/10.1016/j.jhep.2016.01.029#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.69C44DA7
RelevancyScore: 883
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 883.215454101563
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Foster%2C+G%22&quot;&gt;Foster, G&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Irving%2C+W%22&quot;&gt;Irving, W&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cheung%2C+M%22&quot;&gt;Cheung, M&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Walker%2C+A%22&quot;&gt;Walker, A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hudson%2C+B%22&quot;&gt;Hudson, B&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Verma%2C+S%22&quot;&gt;Verma, S&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22McLauchlan%2C+J%22&quot;&gt;McLauchlan, J&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mutimer%2C+D%22&quot;&gt;Mutimer, D&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brown%2C+A%22&quot;&gt;Brown, A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gelson%2C+W%22&quot;&gt;Gelson, W&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22MacDonald%2C+D%22&quot;&gt;MacDonald, D&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Agarwal%2C+K%22&quot;&gt;Agarwal, K&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22HCV+Research%2C+UK%22&quot;&gt;HCV Research, UK&lt;/searchLink&gt;
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Elsevier
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2019
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: Oxford University Research Archive (ORA)
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background &amp; Aims: All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcomes in treated and untreated patients with decompensated cirrhosis. Methods: Patients with HCV and decompensated cirrhosis or at risk of irreversible disease were treated in an expanded access programme (EAP) in 2014. Treatment, by clinician choice, was with sofosbuvir, ledipasvir or daclatasvir, with or without rib-avirin. For functional outcome comparison, untreated patients with HCV and decompensated cirrhosis who were registered on a database 6 months before treatment was available were retro-spectively studied. Primary endpoint was sustained virological response 12 weeks post antiviral treatment (treated cohort) and the secondary endpoint (both cohorts) was adverse outcomes (worsening in MELD score or serious adverse event) within 6 months. Results: 467 patients received treatment (409 decompensated cirrhosis). Viral clearance was achieved in 381 patients (81.6%)– 209 from 231 (90.5%) with genotype 1 and 132 from 192(68.8%) with genotype 3. MELD scores improved in treated patients (mean change -0.85) but worsened in untreated patients (mean + 0.75) (p&lt;0.0001). Patients with initial serumalbumin &lt;35 g/L, aged &gt;65 or with low (&lt;135 mmol/L) baselineserum sodium concentrations were least likely to benefit from therapy. Conclusions: All oral DAAs effectively cured HCV in patients with advanced liver disease. Viral clearance was associated with improvement in liver function within 6 months compared to untreated patients. The longer term impact of HCV treatment in patients with decompensated cirrhosis remains to be determined.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://doi.org/10.1016/j.jhep.2016.01.029
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1016/j.jhep.2016.01.029
– Name: URL
  Label: Availability
  Group: URL
  Data: https://doi.org/10.1016/j.jhep.2016.01.029&lt;br /&gt;https://ora.ox.ac.uk/objects/uuid:72cd8280-5289-4a1d-9eaf-9fe68f2fe2cd
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: info:eu-repo/semantics/openAccess
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.69C44DA7
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.69C44DA7
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jhep.2016.01.029
    Languages:
      – Text: English
    Titles:
      – TitleFull: Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Foster, G
      – PersonEntity:
          Name:
            NameFull: Irving, W
      – PersonEntity:
          Name:
            NameFull: Cheung, M
      – PersonEntity:
          Name:
            NameFull: Walker, A
      – PersonEntity:
          Name:
            NameFull: Hudson, B
      – PersonEntity:
          Name:
            NameFull: Verma, S
      – PersonEntity:
          Name:
            NameFull: McLauchlan, J
      – PersonEntity:
          Name:
            NameFull: Mutimer, D
      – PersonEntity:
          Name:
            NameFull: Brown, A
      – PersonEntity:
          Name:
            NameFull: Gelson, W
      – PersonEntity:
          Name:
            NameFull: MacDonald, D
      – PersonEntity:
          Name:
            NameFull: Agarwal, K
      – PersonEntity:
          Name:
            NameFull: HCV Research, UK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
ResultId 1